Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RESEARCH TOOLSreports
Cartesian Therapeutics (RNAC) Stock Price & Analysis
1,060 Followers
RNAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.67 - $42.60
Previous Close$16.16
Volume92.97K
Average Volume (3M)154.77K
Market Cap
$287.91M
Enterprise Value$221.95M
Total Cash (Recent Filing)$76.91M
Total Debt (Recent Filing)$10.96M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.02
Shares Outstanding17,796,053
10 Day Avg. Volume103,618
30 Day Avg. Volume154,766
Standard Deviation0.24
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-0.64
Price to Sales (P/S)15.60
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit8.54
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$43.25Price Target Upside167.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics: Investment, Director Appointment, and Trial Success
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe Phase 2b results for Descartes-08 are encouraging – establishing proof-of-concept with competitive depth of initial response, promising early signals on durability of effect, and a clean safety profile.
Efficacy And SafetyDescartes-08 has potential to be a safer and re-dosable CAR-T that provides deep and durable efficacy.
Regulatory MilestonesRNAC plans to conduct an End-of-Phase 2 meeting with FDA to align on a potential Phase 3 trial design, with potential to enrich the primary efficacy group and extend the timing for measuring the primary efficacy endpoint.
Bears Say
Clinical TrialsInvestor concern around the potential performance of Descartes-08 on an intent-to-treat basis.
Financial RisksRisks include, but are not limited to, possible long-term dilution risk.
Product DevelopmentRoche/Chugai's recent decision to discontinue further development of Enspryng in MG suggests there's some downside risk even if results are statistically positive.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $42.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Currently, no data Available
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on May 08, 2024. The company reported -$10.5 earnings per share for the quarter, missing the consensus estimate of -$0.885 by -$9.615.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 17,816,238 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$10.5 in its last earnings report, missing expectations of -$0.885. Following the earnings report the stock price went up 0.216%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Among the largest hedge funds holding Cartesian Therapeutics’s share is Delphi Financial Group, Inc.. It holds Cartesian Therapeutics’s shares valued at 430K.
---
Cartesian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.25 (167.64% Upside)
$43.25 (167.64% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 72.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
108.88%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
RNAC Earnings Call
Q2 2023
0:00 / 0:00
---
RNAC Stock 12 Month Forecast
Average Price Target
$43.25
▲(167.64% Upside)
Technical Analysis
Best Analysts Covering RNAC
1 Year
1 Year Success Rate
9/32 ratings generated profit
1 Year Average Return
-19.27%
reiterated a buy rating 19 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 28.13% of your transactions generating a profit, with an average return of -19.27% per trade.
---